King Wealth Management Group Acquires New Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

King Wealth Management Group bought a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 98,102 shares of the company’s stock, valued at approximately $1,768,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Oppenheimer & Co. Inc. increased its stake in shares of Teva Pharmaceutical Industries by 9.6% during the first quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock valued at $191,000 after acquiring an additional 1,180 shares during the period. Sei Investments Co. increased its position in shares of Teva Pharmaceutical Industries by 0.9% in the first quarter. Sei Investments Co. now owns 457,322 shares of the company’s stock worth $6,453,000 after acquiring an additional 4,000 shares in the last quarter. State Board of Administration of Florida Retirement System raised its holdings in shares of Teva Pharmaceutical Industries by 13.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 62,018 shares of the company’s stock valued at $875,000 after acquiring an additional 7,335 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in Teva Pharmaceutical Industries by 36.3% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,691 shares of the company’s stock worth $8,857,000 after purchasing an additional 167,097 shares during the period. Finally, Vanguard Group Inc. raised its stake in Teva Pharmaceutical Industries by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 825,537 shares of the company’s stock valued at $11,648,000 after purchasing an additional 28,071 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Down 1.1 %

Teva Pharmaceutical Industries stock opened at $16.75 on Friday. Teva Pharmaceutical Industries Limited has a 52 week low of $8.64 and a 52 week high of $19.31. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The business’s fifty day moving average is $17.84 and its two-hundred day moving average is $17.20.

Analysts Set New Price Targets

TEVA has been the topic of a number of research analyst reports. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. increased their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. UBS Group upped their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Finally, Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $19.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.